All In Biotech

Drug Trial Radar · NCT07430306

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

245

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

Jan 26, 2029

Study completion Jan 26, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
ICON plc
First posted
Feb 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment. Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • AnifrolumabDrug

    Patients will receive Anifrolumab subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Attainment of DORIS remissionTime frame: At Week 52

Locations

108 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama · Withdrawn

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Fontana, California · Not yet recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    La Palma, California · Recruiting

  • Research Site

    Menifee, California · Recruiting

  • Research Site

    San Leandro, California · Recruiting

  • Research Site

    Temecula, California · Recruiting

  • Research Site

    Brandon, Florida · Not yet recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Miami, Florida · Suspended

  • Research Site

    St. Petersburg, Florida · Not yet recruiting

  • Research Site

    Willowbrook, Illinois · Recruiting

  • Research Site

    New Albany, Indiana · Recruiting

  • Research Site

    Lake Charles, Louisiana · Recruiting

  • Research Site

    Silver Spring, Maryland · Recruiting

  • Research Site

    Kansas City, Missouri · Recruiting

  • Research Site

    West Long Branch, New Jersey · Recruiting

  • Research Site

    Oklahoma City, Oklahoma · Not yet recruiting

  • Research Site

    Oklahoma City, Oklahoma · Recruiting

  • Research Site

    Memphis, Tennessee · Not yet recruiting

  • Research Site

    Memphis, Tennessee · Recruiting

  • Research Site

    Austin, Texas · Not yet recruiting

  • Research Site

    Baytown, Texas · Recruiting

  • Research Site

    Colleyville, Texas · Recruiting

  • Research Site

    Edinburg, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Sugar Land, Texas · Recruiting

  • Research Site

    Spokane, Washington · Recruiting

  • Research Site

    Calgary, Alberta, Canada · Not yet recruiting

  • Research Site

    Richmond, British Columbia, Canada · Not yet recruiting

  • Research Site

    Winnipeg, Manitoba, Canada · Not yet recruiting

  • Research Site

    Hamilton, Ontario, Canada · Not yet recruiting

  • Research Site

    Toronto, Ontario, Canada · Not yet recruiting

  • Research Site

    Clermont-Ferrand, France · Recruiting

  • Research Site

    Lyon, France · Recruiting

  • Research Site

    Marseille, France · Recruiting

Showing 40 of 108 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.